| Texto completo | |
| Autor(es): Mostrar menos - |
de Souza, Joao Victor Marcelino
;
Costa, Natalia C. S.
;
Brasil, Maria C. O. Arruda
;
dos Anjos, Luana Ribeiro
;
de Menezes, Renata Priscila Barros
;
Zampieri, Eduardo Henrique
;
de Lima, Jhonatan Santos
;
Velasquez, Angela Maria Arenas
;
Scotti, Luciana
;
Scotti, Marcus Tullius
;
Graminha, Marcia A. S.
;
Gonzalez, Eduardo R. Perez
;
Cilli, Eduardo Maffud
Número total de Autores: 13
|
| Tipo de documento: | Artigo Científico |
| Fonte: | Molecules; v. 30, n. 2, p. 17-pg., 2025-01-01. |
| Resumo | |
Leishmaniasis is a neglected tropical disease caused by a protozoan of the genus Leishmania, which has visceral and cutaneous forms. The symptoms of leishmaniasis include high fever and weakness, and the cutaneous infection also causes lesions under the skin. The drugs used to treat leishmaniasis have become less effective due to the resistance mechanisms of the protozoa. In addition, the current compounds have low selectivity for the pathogen, leading to various side effects, which results in lower adherence to treatment. Various strategies were developed to solve this problem. The bioconjugation between natural compounds with antimicrobial activity and cell-penetrating peptides could alleviate the resistance and toxicity of current treatments. This work aims to conjugate the cell penetration peptide TAT to the guanidine GVL1. The GVL1-TAT bioconjugate exhibited leishmanicidal activity against Leishmania amazonensis and Leishmania infantum with a high selectivity index. In addition, the bioconjugate was more active against the intracellular enzyme CPP than the individual compounds. This target is very important for the viability and virulence of the parasite within the host cell. Docking studies confirmed the higher interaction of the conjugate with CPP and suggested that other proteins, such as trypanothione reductase, could be targeted. Thus, the data indicated that guanidines conjugated with cell-penetrating peptides could be a good approach for developing antileishmanial molecules. (AU) | |
| Processo FAPESP: | 21/02595-8 - Caracterização estrutural e biológica de Guanidinas sintéticas como potenciais agentes contra a Leishmaniose cutânea e visceral |
| Beneficiário: | Eduardo Rene Perez Gonzalez |
| Modalidade de apoio: | Auxílio à Pesquisa - Regular |
| Processo FAPESP: | 20/04415-4 - Terapêutica para as leishmanioses: do screening ao estudo de mecanismos de ação, uma contribuição para a descoberta de novas moléculas antileishmaniais |
| Beneficiário: | Marcia Aparecida Silva Graminha |
| Modalidade de apoio: | Auxílio à Pesquisa - Regular |
| Processo FAPESP: | 13/07600-3 - CIBFar - Centro de Inovação em Biodiversidade e Fármacos |
| Beneficiário: | Glaucius Oliva |
| Modalidade de apoio: | Auxílio à Pesquisa - Centros de Pesquisa, Inovação e Difusão - CEPIDs |
| Processo FAPESP: | 22/05411-8 - Desenvolvimento de bioconjugados peptídeos/guanidinas com atividade anti-Leishmania |
| Beneficiário: | Eduardo Maffud Cilli |
| Modalidade de apoio: | Auxílio à Pesquisa - Regular |